TANGO THERAPEUTICS INC. - COMMON STOCK

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

25 Mar 2025 15:30:00 By Nasdaq GlobeNewswire

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights 

27 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences

20 Feb 2025 06:30:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

30 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

05 Mar 2024 15:47:49 By Nasdaq GlobeNewswire

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

31 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers

03 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

13 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

08 Nov 2023 06:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

07 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

18 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

06 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Updates to Its Board of Directors

29 Aug 2023 16:08:05 By Nasdaq GlobeNewswire

Tango Therapeutics Announces $80 million Private Placement Financing

10 Aug 2023 06:00:19 By Nasdaq GlobeNewswire

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

07 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

10 Jul 2023 06:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in Upcoming Investor Conferences

01 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

09 May 2023 06:00:03 By Nasdaq GlobeNewswire

Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

18 Apr 2023 15:30:00 By Nasdaq GlobeNewswire